TRAW

TRAW

Traws Pharma, Inc.

0.60 USD

Last updated Sep 5, 11:24 UTC

Yesterday HIGH

$0.57

Yesterday LOW

$0.54

52w HIGH

$3.25

52w LOW

$0.43

EPS

-0.16

PE

-3.73

Next Earnings

Nov 12, 2026

Overview News Government Trades Fundamentals

Traws Pharma, Inc. stock is up 10.51% since 30 days ago. The next earnings date is Nov 12, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 35.71% of the previous 13 September’s closed higher than August. 0% of analysts rate it a buy.

Snigdha Gairola

Mon May 11, 2026

Chuck Schumer Blasts Trump, Elon Musk For Firing CDC And Port Health Workers As Hantavirus Scare Grips The World

Hantavirus outbreak on a cruise ship sparks alarm as Schumer blames CDC cuts, warning weakened disease surveillance and calling for urgent reforms.
Benzinga Insights

Fri May 8, 2026

12 Health Care Stocks Moving In Friday's Intraday Session
Vandana Singh

Fri May 8, 2026

Traws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship Outbreak

Traws Pharma shares jump after the company advanced hantavirus antiviral candidates amid global monitoring of a cruise ship outbreak.
Benzinga Newsdesk

Fri May 8, 2026

Traws Pharma shares are trading higher after the company announced plans to advance potential clinical candidates for the treatment of hantavirus infections.
Benzinga Insights

Fri May 8, 2026

12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Newsdesk

Fri May 8, 2026

Traws Pharma Announces Plans To Advance Potential Clinical Candidates For The Treatment Of Hantavirus Infection

Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral
Benzinga Insights

Wed Apr 29, 2026

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Newsdesk

Wed Apr 15, 2026

Traws Pharma Q4 EPS $(0.71) Misses $(0.69) Estimate

Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.69) by 2.9 percent. This is a 85.8 percent increase over losses of $(5.00) per share from the
Benzinga Insights

Wed Apr 15, 2026

12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Newsdesk

Wed Apr 15, 2026

Traws Pharma Prices $10M PIPE At $1.673/Share For 5.98M Shares, Issues Warrants For Up To 29.9M Shares With $50M Additional Upside Potential

Entry into a Material Definitive Agreement PIPE Securities Purchase Agreement On April 15, 2026, Traws Pharma, Inc. (the "Company") announced the pricing of an offering (the "Private Placement") of an aggregate

HC Wainwright & Co.

Tue Aug 18, 13:29

hold

confirm

Advanced Data Unlock

UVXY $17.35 USD

BRUN BRUN $17.34 USD

ALOY ALOY $10.10 USD

AMRN $13.63 USD

HROW $38.54 USD

CRCL $101.56 USD

MSTX MSTX $16.80 USD

VKTX $34.86 USD